Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice
Tóm tắt
Highly pathogenic avian H5N1 influenza virus is a major public health concern. Given the lack of effective vaccine and recent evidence of antiviral drug resistance in some isolates, alternative strategies for containment of a possible future pandemic are needed. Humanized monoclonal antibodies (mAbs) that neutralize H5N1 virus could be used as prophylaxis and treatment to aid in the containment of such a pandemic. Neutralizing mAbs against H5 hemagglutinin were humanized and introduced into C57BL/6 mice (1, 5, or 10 mg/kg bodyweight) one day prior to-, one day post- and three days post-lethal challenge with H5N1 A/Vietnam/1203/04 virus. Efficacy was determined by observation of weight loss as well as survival. Two mAbs neutralizing for antigenically variant H5N1 viruses, A/Vietnam/1203/04 and A/Hong Kong/213/03 were identified and humanized without loss of specificity. Both antibodies exhibited prophylactic efficacy in mice, however, VN04-2-huG1 performed better requiring only 1 mg/kg bodyweight for complete protection. When used to treat infection VN04-2-huG1 was also completely protective, even when introduced three days post infection, although higher dose of antibody was required. Prophylaxis and treatment using neutralizing humanized mAbs is efficacious against lethal challenge with A/Vietnam/1203/04, providing proof of principle for the use of passive antibody therapy as a containment option in the event of pandemic influenza.
Tài liệu tham khảo
Claas EC, Osterhaus AD, van Beek R, De Jong JC, Rimmelzwaan GF, Senne DA, Krauss S, Shortridge KF, Webster RG: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998,351(9101):472–477.
Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, Cheung PT, To WK, Ho ET, Sung R, Cheng AF: Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998,351(9101):467–471.
de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL: A pandemic warning? Nature 1997,389(6651):554.
Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Rahardjo AP, Puthavathana P, Buranathai C, Nguyen TD, Estoepangestie AT, Chaisingh A, Auewarakul P, Long HT, Hanh NT, Webby RJ, Poon LL, Chen H, Shortridge KF, Yuen KY, Webster RG, Peiris JS: Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004,430(6996):209–213.
Keawcharoen J, Oraveerakul K, Kuiken T, Fouchier RA, Amonsin A, Payungporn S, Noppornpanth S, Wattanodorn S, Theambooniers A, Tantilertcharoen R, Pattanarangsan R, Arya N, Ratanakorn P, Osterhaus DM, Poovorawan Y: Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis 2004,10(12):2189–2191.
Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R, Osterhaus A: Avian H5N1 influenza in cats. Science 2004,306(5694):241.
Fouchier R, Kuiken T, Rimmelzwaan G, Osterhaus A: Global task force for influenza. Nature 2005,435(7041):419–420.
Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM: Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004,4(8):499–509.
Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster RG: Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004,363(9415):1099–1103.
Wood JM, Robertson JS: From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2004,2(10):842–847.
Hien TT, Liem NT, Dung NT, San LT, Mai PP, Chau NV, Suu PT, Dong VC, Mai LTQ, Thi NT, Khoa DB, Phat LP, Truong NT, Long HT, Tung CV, Giang LT, Tho ND, Nga LH, Tien NTK, San LH, Tuan LV, Dolecek C, Thanh TT, de Jong M, Schultsz C, Cheng P, Lim W, Horby P, the World Health Organization International Avian Influenza Investigative T, Farrar J: Avian Influenza A (H5N1) in 10 Patients in Vietnam. N Engl J Med 2004,350(12):1179–1188.
Yen HL, Monto AS, Webster RG, Govorkova EA: Virulence May Determine the Necessary Duration and Dosage of Oseltamivir Treatment for Highly Pathogenic A/Vietnam/1203/04 Influenza Virus in Mice. J Infect Dis 2005,192(4):665–672.
de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau NV, Cam BV, Qui PT, Ha DQ, Guan Y, Peiris JSM, Hien TT, Farrar J: Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection. N Engl J Med 2005,353(25):2667–2672.
Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KHL, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y: Avian flu: Isolation of drug-resistant H5N1 virus. Nature 2005,437(7062):1108–1108.
Hayden F, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J, Macken C, Hampson A, Webster RG, Amyard M, Zambon M: Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 2005,10(8):873–877.
Sawyer LA: Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000,47(2):57–77.
Ramisse F, Deramoudt FX, Szatanik M, Bianchi A, Binder P, Hannoun C, Alonso JM: Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments. Clin Exp Immunol 1998,111(3):583–587.
Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W: A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 1997,71(6):4347–4355.
Okuno Y, Matsumoto K, Isegawa Y, Ueda S: Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol 1994,68(1):517–520.
Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X: Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respiratory Research 2006,7(1):43.
Bleeker WK, Agterberg J, Rigter G, van Rooijen N, Bakker JC: Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin Exp Immunol 1989,77(3):338–344.
Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG: Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A 2005,102(36):12915–12920.
Kohler G, Milstein C: Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol 1976,6(7):511–519.
Jostock T, Vanhove M, Brepoels E, Van Gool R, Daukandt M, Wehnert A, Van Hegelsom R, Dransfield D, Sexton D, Devlin M, Ley A, Hoogenboom H, Mullberg J: Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. J Immunol Methods 2004,289(1–2):65–80.
Lennon G, Auffray C, Polymeropoulos M, Soares MB: The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression. Genomics 1996,33(1):151–152.
Chen H, Smith GJ, Li KS, Wang J, Fan XH, Rayner JM, Vijaykrishna D, Zhang JX, Zhang LJ, Guo CT, Cheung CL, Xu KM, Duan L, Huang K, Qin K, Leung YH, Wu WL, Lu HR, Chen Y, Xia NS, Naipospos TS, Yuen KY, Hassan SS, Bahri S, Nguyen TD, Webster RG, Peiris JS, Guan Y: Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control. Proc Natl Acad Sci U S A 2006,103(8):2845–2850.
Skehel JJ, Wiley DC: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531–569.
Wiley DC, Wilson IA, Skehel JJ: Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981,289(5796):373–378.
Caton AJ, Brownlee GG, Yewdell JW, Gerhard W: The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982,31(2 Pt 1):417–427.
Ha Y, Stevens DJ, Skehel JJ, Wiley DC: H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes. Embo J 2002,21(5):865–875.
Laffly E, Sodoyer R: Monoclonal and recombinant antibodies, 30 years after. Hum Antibodies 2005,14(1–2):33–55.
Ferguson NM, Cummings DAT, Cauchemez S, Fraser C, Riley S, Meeyai A, Iamsirithaworn S, Burke DS: Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 2005,437(7056):209–214.
Longini IMJ, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DAT, Halloran ME: Containing Pandemic Influenza at the Source. Science 2005,309(5737):1083–1087.
Fleury D, Wharton SA, Skehel JJ, Knossow M, Bizebard T: Antigen distortion allows influenza virus to escape neutralization. Nat Struct Biol 1998,5(2):119–123.
Bizebard T, Gigant B, Rigolet P, Rasmussen B, Diat O, Bosecke P, Wharton SA, Skehel JJ, Knossow M: Structure of influenza virus haemagglutinin complexed with a neutralizing antibody. Nature 1995,376(6535):92–94.